Core Viewpoint - The company, UBTECH Robotics, has issued a warning to the public regarding fraudulent activities using its name, urging users to be vigilant against scams [2][10]. Group 1: Fraudulent Activities - Fraudsters are using deceptive apps and social media tactics, such as "team incentives" and "red envelope draws," to lure users into providing sensitive personal information like phone numbers and ID numbers [4][10]. - Scammers are promoting a fake app called "UBTECH Business Version" through various platforms, enticing users with promises of high returns and investment rebates, ultimately leading to financial loss [10]. Group 2: Official Communication and Verification - The company has provided official contact methods, including its website and verified social media accounts, to help users distinguish between legitimate and fraudulent communications [5][6]. - UBTECH emphasizes that it will never request sensitive information such as bank card verification codes and that all business processes will be clearly communicated through official channels [6]. Group 3: Legal Actions and User Protection - The company has reported the fraudulent activities to law enforcement and is committed to taking legal action against those misusing its name [7][10]. - UBTECH reassures users of its dedication to protecting their rights and maintaining the integrity of its brand [10]. Group 4: Company Background and Financial Performance - UBTECH was founded in March 2012 and went public on December 29, 2023 [11]. - In 2024, the company achieved a revenue of 1.305 billion yuan, a year-on-year increase of 23.7%, with a gross profit of 374 million yuan, up 12.4%, and a net loss of 1.16 billion yuan, narrowing by 8.3% compared to the previous year [12].

Core Viewpoint - The AI Fund Zhonghai Healthcare Theme Stock A (399011) reported a profit of 3.327 million yuan for Q2 2025, with a weighted average profit per fund share of 0.007 yuan, and a net asset value growth rate of 0.56% during the period [2]. Fund Performance - As of July 18, the fund's unit net value was 1.15 yuan, with a fund size of 493 million yuan [2][15]. - The fund's one-year return rate was 14.88%, ranking 48 out of 53 comparable funds [3]. - Over the past three months, the fund's return rate was 9.42%, ranking 51 out of 54 comparable funds [3]. Investment Strategy - The fund focuses on innovative drugs, medical devices, and healthcare services driven by consumer upgrades, aiming to identify quality stocks with growth potential and matching valuation levels [2]. - The fund employs a bottom-up stock selection strategy, maintaining quality assets while exploring undervalued stocks to reduce portfolio volatility and provide stable long-term returns [2]. Risk and Volatility - The fund's three-year maximum drawdown was 42.54%, ranking 17 out of 46 comparable funds [10]. - The fund's Sharpe ratio over the past three years was -0.2182, ranking 40 out of 46 comparable funds [8]. Portfolio Composition - The fund has a high concentration of holdings, with the top ten stocks consistently exceeding 60% over the past two years [17]. - As of Q2 2025, the top ten holdings included companies such as Heng Rui Pharmaceutical, Zai Lab, and BeiGene [17].

Investment Rating - The industry investment rating is "stronger than the market," indicating that the industry index is expected to outperform the market by more than 5% over the next six months [56]. Core Insights - The report highlights the rapid pace of the implementation of the 11th batch of national centralized procurement, with 55 varieties included, a decrease of 7 from the previous batch. The average price drop in past procurement batches ranged from 48% to 59% [4][10]. - The total sales scale of the 11th batch of procurement varieties in medical institutions is projected to exceed 49 billion yuan in 2024 [10]. - The report identifies key therapeutic areas for the 55 varieties, including blood and hematopoietic system drugs, digestive system and metabolic drugs, respiratory system drugs, and others, with varying numbers of products in each category [10][11]. Summary by Sections National Procurement Overview - The 11th batch of national centralized procurement includes 55 varieties, with a total of 515 varieties across all batches. The average price drop in previous batches was between 48% and 59% [4][6]. - The timeline from the release of procurement documents to the announcement of selected results is approximately 1-2 months, followed by 3-4 months for implementation [4][7]. Competitive Landscape - Among the 55 varieties, 37 have 10 or more qualifying companies, with 4 having 30 or more. The leading companies in terms of the number of approved varieties include Beite Pharmaceutical, Kelun Pharmaceutical, and Fosun Pharma [10][12]. Changes in Procurement Rules - The report outlines changes in procurement rules for the 11th batch, including reasons for exclusion of certain products, such as low annual procurement amounts and high clinical risks [16][19]. - The reporting method for medical institutions has shifted from generic names to specific brand names for reporting quantities [19]. Sales and Market Share - The report provides a detailed table of the expected sales and market share for various products in the 11th batch, highlighting significant sales figures for products like Dapagliflozin and Olaparib, with market shares reaching up to 100% for some products [24][26]. Investment Strategy - The report suggests focusing on innovative pharmaceutical companies with rich pipeline layouts, such as Heng Rui Medicine and BeiGene, as well as companies with significant single-product potential and leading technology platforms [30].

Group 1 - The core viewpoint is that the investment enthusiasm for medical AI products is increasing overseas, with significant financing events related to medical AI electronic medical record products [1] - In June 2025, the global healthcare sector saw 144 financing events, with disclosed amounts reaching approximately $2.2 billion, highlighting innovative drugs as a hot financing area in China's healthcare sector [1] - The largest disclosed financing amounts in June 2025 for innovative drugs were $2 million each for Tianchen Biotech, Sipure, and Baiquan Biotech, focusing on allergy and cancer drug development [1] Group 2 - There is a notable difference in financing preferences between overseas and Chinese medical device sectors, with overseas favoring cutting-edge innovations like medical AI electronic medical records, while China focuses on cardiovascular interventions [2] - The top three disclosed financing amounts in China's medical device sector were for companies involved in vascular intervention devices and high-end interventional medical devices [2] Group 3 - The bidding data for medical devices continues to show growth, with significant increases in sales for CT, MRI, and ultrasound devices in June 2025 [3] - Specific sales figures include CT at $1.9 billion (yoy +63%), MRI at $1.5 billion (yoy +65%), and ultrasound at $1.4 billion (yoy +50%) [3] - The sales figures for blood/purification dialysis devices and gene sequencing instruments also show strong recovery, with $324 million (yoy +54%) and $65 million (yoy +50%) respectively [3]

Summary of Key Points from Conference Call Records Industry Overview: Medical Devices in Hong Kong and A-Share Market - The Hong Kong medical device sector is characterized by innovative product launches, technological breakthroughs, and companies with strong cash flow and rapid earnings growth, particularly the 18A category companies, some of which have seen stock price increases exceeding 100% [1][4] - In the A-share market, various segments such as medical devices, high-value consumables, low-value consumables, and in vitro diagnostics exhibit different business models and investment logics, with varying inflection points [1][5] Key Companies and Investment Opportunities - **Orthopedic Sector**: Companies like Chuangli Medical and Aikang Medical are highlighted for their strong performance and growth potential, particularly in the context of cleared material prices and robust international business growth [1][4] - **Cardiovascular Devices**: Companies such as MicroPort Medical, Guizhuang Tongxiao, and Xianruida are noted for their promising developments in the cardiovascular device space [1][4] - **Neurointervention**: MicroPort Medical is expected to turn profitable by the end of 2024, with projected profit growth of 50% from 2025 to 2027, benefiting from procurement policies [1][15] Financial Performance and Projections - MicroPort Medical achieved profitability in 2024 with a profit of 100 million yuan, and anticipates a 50% annual profit growth from 2025 to 2027 [1][15] - Heartway Medical is expected to improve significantly in profitability by 2025-2026, leveraging a low-price strategy to counteract procurement pressures [2][19] - Baixin An's stock has surged by 156%, with its core product RDN targeting a large market for resistant hypertension, indicating substantial growth potential [2][26] Market Trends and Structural Opportunities - The medical device sector is expected to see structural opportunities in the second half of 2025, driven by low comparative bases from 2024 and favorable policy changes [2] - The peripheral intervention industry is projected to experience accelerated domestic replacement rates, with national procurement results expected in early 2025 [2][16] Emerging Technologies and Long-term Value - The brain-computer interface sector is advancing rapidly, with expectations for breakthroughs in motor and language control, and companies like Mindray and Nanhui are noted for their long-term investment value [1][7][8] - Companies such as Weitai Medical are developing innovative products like the second-generation CGM, which is expected to gain market traction [12] Challenges and Strategic Responses - Companies like Times Angel are facing pressure in domestic business growth but are expected to maintain high growth in overseas markets despite challenges [11] - The neurointervention sector has seen rapid domestic growth despite price reductions, with companies like MicroPort Brain Science achieving significant overseas revenue growth [24][25] Conclusion - The medical device industry in both Hong Kong and A-share markets presents numerous investment opportunities, particularly in innovative companies with strong growth trajectories and strategic responses to market challenges. Investors are encouraged to monitor these developments closely for potential gains [20][21]

Core Viewpoints - The pharmaceutical and biotechnology sector is experiencing a turning point and structural market trends in the first half of 2025, with a focus on innovative drugs and their supply chain, AI healthcare, and brain-computer interfaces as structural opportunities [3][5] - The A-share pharmaceutical and biotechnology index has increased by 10.10% since the beginning of 2025, outperforming the CSI 300 index by 8.90 percentage points, ranking 4th in industry performance [3][22] - Among 480 listed pharmaceutical and biotechnology companies, 348 have seen their stock prices rise, accounting for 72.5%, with 17 stocks doubling in value [3][40] Investment Logic - The innovative drug sector is accelerating its value reconstruction through business development (BD) overseas, research and commercialization progress, and policy support. In the first half of 2025, over 50 BD transactions for innovative drugs occurred, totaling over $48 billion [5] - Significant clinical data releases and commercialization progress for major drug candidates are expected to drive stock price increases [5] - Policy initiatives, such as the March 2025 government work report emphasizing the support for innovative drugs and medical devices, are providing strong backing for the industry's long-term development [5] Market Performance - The pharmaceutical sector's valuation has seen a short-term recovery but remains at a long-term low, with a PE ratio of 29 times as of mid-2025, slightly above the 50th percentile of the past four years [3][43] - Public fund holdings in the pharmaceutical sector have increased, with the proportion of public funds in A+H shares rising to 9.05% in Q1 2025, a 0.37 percentage point increase [3][58] Sub-industry Performance - The best-performing sub-industries in the pharmaceutical sector include chemical preparations and other biological products, with increases of 25.8% and 24.0%, respectively [3][22] - The pharmaceutical industry is witnessing a structural market trend, with innovative drugs leading the charge, while traditional sectors like vaccines and traditional Chinese medicine have seen slight declines [3][29] Recommended Stocks - A robust portfolio is suggested, including companies such as Heng Rui Medicine, BeiGene, and United Imaging Healthcare, among others [10]

2025 年 07 月 20 日 投资评级：看好（维持） 医药生物 行业走势图 -24% -12% 0% 12% 24% 36% 2024-07 2024-11 2025-03 医药生物 沪深300 数据来源：聚源 相关研究报告 《CXO 龙头中报业绩超预期，重点关 注板块后续行情 — 行 业 周 报 》 -2025.7.13 《艾伯维收购 Capstan，加码体内 CAR-T—行业周报》-2025.7.6 《多款减肥药亮相 2025 ADA，重点关 注 AMYR 与 ActRII 靶点—行业周报》 -2025.6.29 集采政策明确优化，继续推荐制药板块性机会 ——行业周报 | 余汝意（分析师） | 刘艺（联系人） | 聂媛媛（联系人） | | --- | --- | --- | | yuruyi@kysec.cn | liuyi1@kysec.cn | nieyuanyuan@kysec.cn | | 证书编号：S0790523070002 | 证书编号：S0790124070022 | 证书编号：S0790124050002 | 集采政策持续优化，仿创 pharma 有望估值重塑 集采政策优化基调明确， ...

Group 1 - The net asset value of the China Europe Fund's China Europe CSI All-Share Healthcare Equipment and Services Index Fund A (021714) as of June 30, 2025, is 0.12 billion yuan, representing a decrease of 7.74% compared to the previous period [1] - The fund manager, Song Weiwei, has extensive experience and has held multiple managerial positions in various funds since 2024 [2] - Recent changes in fund share scale indicate a total share of 0.02 billion as of June 30, 2025, with a net asset change rate of -24.80% [3] Group 2 - The fund's performance shows a 3-month return of 7.22%, a 1-year return of 9.65%, and a cumulative return since inception of 9.65% [3] - The top ten stock holdings of the fund include Mindray Medical, United Imaging Healthcare, Aier Eye Hospital, and others, with a combined holding percentage of 42.08% [3] - China Europe Fund Management Co., Ltd. was established in July 2006, located in Shanghai, with a registered capital of 220 million yuan [3]

Core Viewpoint - The company, Shanghai United Imaging Healthcare Co., Ltd., has announced a differentiated cash dividend distribution plan for the year 2024, which was approved at the annual shareholders' meeting on June 30, 2025 [1][2]. Dividend Distribution Plan - The company plans to distribute a cash dividend of 0.08 yuan per share (including tax) to all shareholders, with a total cash dividend amounting to approximately 65.6 million yuan (including tax) based on a total share capital of 824,157,988 shares [2][3]. - The distribution will not include capital reserve transfers to increase share capital or stock dividends [2][3]. Relevant Dates - The key dates for the dividend distribution are as follows: - Record date for shareholding: To be determined - Ex-dividend date: To be determined - Cash dividend payment date: To be determined [4]. Tax Implications - For individual shareholders holding shares for more than one year, the dividend income is exempt from personal income tax, resulting in a net cash dividend of 0.08 yuan per share [5][6]. - For shares held for less than one year, the company will not withhold personal income tax at the time of distribution; however, tax will be calculated and withheld upon the transfer of shares [5][6]. - For qualified foreign institutional investors (QFIIs), a 10% corporate income tax will be withheld, resulting in a net cash dividend of 0.072 yuan per share [7][8]. Implementation Method - The cash dividends will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch, to shareholders registered on the record date [4]. - Shareholders who have completed designated transactions can receive their cash dividends on the payment date at their designated securities firms [4].

中信证券股份有限公司、中国国际金融股份有限公司 关于上海联影医疗科技股份有限公司 差异化分红事项的核查意见 中信证券股份有限公司（以下简称"中信证券"、"保荐人"）、中国国际金 融股份有限公司（以下简称"中金公司"、"保荐人"）为上海联影医疗科技股份 有限公司（以下简称"公司"、"联影医疗"）首次公开发行股票并上市的保荐人。 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和 国证券法》（以下简称"《证券法》"）及《上海证券交易所上市公司自律监 管指引第 7 号——回购股份》等有关规定，对公司 2024 年度利润分配所涉及的 差异化分红（以下简称"本次差异化分红"）进行了审慎核查，具体情况如下： 一、本次差异化分红的原因 2023 年 8 月 22 日，公司召开了第一届董事会第二十二次会议，审议通过 了《关于以集中竞价交易方式回购公司股份方案的议案》，同意公司以集中竞 价交易方式回购公司股份，回购资金总额不低于人民币 4 亿元（含），不超过 人民币 8 亿元（含），回购股份将在未来适宜时机全部用于公司员工持股计划 或股权激励，回购期限自董事会审议通过本次回购方案之日起 12 个月内。截至 2 ...